EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial

Renning Zheng iD, James P Daniels, James M Mirocha, Alexander Hernández-Tirado iD, Daniel M Moreira, Jay H Fowke, Stephen J Freedland iD

The Prostate · 2026-06 · 86 (8) · 858-864

DOI: 10.1002/pros.70154 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Prostate, online erschienen am 12.03.2026. Verfasst von Renning Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Lower Urinary Tract Symptoms, Prostatic Hyperplasia, Prostatic Neoplasms. Die Arbeit nennt 21 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously found that higher insulin resistance (IR) was associated with larger prostate size and greater risk of benign prostatic hyperplasia (BPH). Since BPH is the most common cause of lower urinary tract symptoms (LUTS), we investigated whether IR is also linked to incidence and progression of LUTS in the REDUCE study, a 4‐year randomized trial of dutasteride vs. placebo for prostate cancer prevention.

Methods

Participants were required to complete the International Prostate Symptom Score (IPSS) questionnaire at recruitment and every subsequent 6 months. Fasting insulin and glucose levels were measured at study baseline, and Homeostatic Model Assessment of Insulin Resistance (HOMA‐IR) was calculated based on these values. Multivariable Cox regression was used to assess associations between HOMA‐IR and (1) LUTS incidence among asymptomatic patients (baseline IPSS < 8); or (2) LUTS progression among symptomatic patients (baseline IPSS ≥ 8) respectively.

Results

As previously reported within this cohort, at baseline, higher HOMA‐IR quartiles were correlated with larger prostate volumes among both asymptomatic ( N = 2745; p < 0.001) and symptomatic patients ( N = 1942; p = 0.007). However, among asymptomatic patients, HOMA‐IR whether analyzed as a continuous ( p = 0.74) or categorized variable (all p ≥ 0.60) was not associated with LUTS incidence in multivariable analysis. Similarly, in symptomatic participants, no associations were found between HOMA‐IR and LUTS progression in multivariable analyses, whether HOMA‐IR was assessed as a categorical (all p ≥ 0.46) or continuous variable ( p = 0.83).

Conclusions

Although IR was linked to larger prostate volumes, it was not an independent risk factor of LUTS development or progression despite the known associations between BPH and LUTS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceLower Urinary Tract SymptomsProstatic HyperplasiaProstatic NeoplasmsAzasteroidsMaleHumansDutasterideAgedMiddle AgedDisease Progression5-alpha Reductase InhibitorsProstate

Stichwörter der Autor:innen

benign prostatic hyperplasiainsulin resistancelower urinary tract symptomsprostate volume

Substanzen

Dutasteride5-alpha Reductase InhibitorsAzasteroids

Autor:innen und Institutionen

  • Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Tsinghua Medicine, Tsinghua University, Beijing, China.
  • Department of Urology, University of Louisville, Louisville, Kentucky, USA.
  • Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Department of Urology, College of Medicine, University of Illinois Chicago, Chicago, Illinois, USA.
  • Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

ORCID-Profile: Renning Zheng, Alexander Hernández-Tirado, Stephen J Freedland

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Zheng, R., Daniels, J. P., Mirocha, J. M., Hernández-Tirado, A., Moreira, D. M., Fowke, J. H., & Freedland, S. J. (2026). Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. The Prostate, 86(8), 858-864. https://doi.org/10.1002/pros.70154

Vancouver

Zheng R, Daniels JP, Mirocha JM, Hernández-Tirado A, Moreira DM, Fowke JH, et al. Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. The Prostate. 2026;86(8):858-864. doi:10.1002/pros.70154

BibTeX
@article{Zheng2026,
  author = {Zheng, Renning and Daniels, James P and Mirocha, James M and Hernández-Tirado, Alexander and Moreira, Daniel M and Fowke, Jay H and Freedland, Stephen J},
  title = {Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {8},
  pages = {858--864},
  doi = {10.1002/pros.70154}
}
Kostenlos starten →